section name header

Pronunciation

GLOO-ka-gon

Classifications

Therapeutic Classification: hormones

Pharmacologic Classification: pancreatics

Indications

REMS

Unlabeled Uses:

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Well absorbed following IM, intranasal, and SUBQ administration; IV administration results in complete bioavailability.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Extensively metabolized by the liver, plasma, and kidneys.

Half-life: 8–18 min.

Time/Action Profile

ROUTEONSETPEAKDURATION
IM (hyperglycemic action)within 10 min30 min12–27 min
IV (hyperglycemic action)1 min5 min9–17 min
SUBQ (hyperglycemic action)within 10 min30–45 min60–90 min
Intranasal (hyperglycemic action)within 15 minunknownunknown
IV (effect on GI musculature)45 sec (for 0.25–2-mg dose)unknown9–17 min (0.25–0.5-mg dose); 22–25 min (2-mg dose)
IM (effect on GI musculature)8–10 min (1-mg dose); 4–7 min (2-mg dose)unknown9–27 min (1-mg dose); 21–32 min (2-mg dose)

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension.

Derm: necrolytic migratory erythema.

EENT: epistaxis, eye redness, itchy eyes, itchy throat, nasal congestion, nasal discomfort, nasal itching, rhinorrhea, sneezing, watery eyes.

GI: nausea, vomiting.

Neuro: headache.

Resp: cough.
Misc: (INCLUDING ANAPHYLAXIS)HYPERSENSITIVITY REACTIONS .

Interactions

Drug-Drug:

Route/Dosage

see Calculator

Hypoglycemia

Radiographic Examination of the GI Tract

Beta Blocker or Calcium Channel Blocker Overdose

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Baqsimi, GlucaGen, Gvoke